Mounjaro leads to significantly more weight loss than Ozempic, study suggests

People taking tirzepatide injections achieved greater weight loss and were more likely to reach weight loss targets compared to those taking semaglutide, according to a study analyzing electronic health records. The study found that 82% of people on tirzepatide reached a 5% weight loss benchmark, compared to approximately 67% on semaglutide. Tirzepatide users were also twice as likely to lose at least 15% of their starting weight. Average weight loss was consistently higher among tirzepatide users at three, six, and twelve months. Both medications mimic the gut hormone GLP-1 to stimulate insulin production.